<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37126136</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>17</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1434-9949</ISSN><JournalIssue CitedMedium="Internet"><Volume>42</Volume><Issue>8</Issue><PubDate><Year>2023</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Clinical rheumatology</Title><ISOAbbreviation>Clin Rheumatol</ISOAbbreviation></Journal><ArticleTitle>Ocular retinal findings in asymptomatic patients with antiphospholipid syndrome secondary to systemic lupus erythematosus.</ArticleTitle><Pagination><StartPage>2105</StartPage><EndPage>2114</EndPage><MedlinePgn>2105-2114</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10067-023-06613-9</ELocationID><Abstract><AbstractText>The objective is to perform a multimodal ophthalmological evaluation, including optical coherence angiography (OCTA), asymptomatic APS secondary to SLE (APS/SLE), and compare to SLE patients and control group (CG). We performed a complete structural/functional ophthalmological evaluation using OCTA/microperimetry exam in all participants. One hundred fifty eyes/75 asymptomatic subjects [APS/SLE (n&#x2009;=&#x2009;25), SLE (n&#x2009;=&#x2009;25), and CG (n&#x2009;=&#x2009;25)] were included. Ophthalmologic abnormalities occurred in 9 (36%) APS/SLE, 11 (44%) SLE, and none of CG (p&#x2009;&lt;&#x2009;0.001). The most common retinal finding was Drusen-like deposits (DLDs) exclusively in APS/SLE and SLE (16% vs. 24%, p&#x2009;=&#x2009;0.75) whereas severe changes occurred solely in APS/SLE [2 paracentral acute middle maculopathy (PAMM) and 1 homonymous quadrantanopsia]. A trend of higher frequency of antiphospholipid antibody (aPL) triple positivity (100% vs. 16%, p&#x2009;=&#x2009;0.05) and higher mean values of adjusted Global Antiphospholipid Syndrome Score (aGAPSS) (14&#x2009;&#xb1;&#x2009;0 vs. 9.69&#x2009;&#xb1;&#x2009;3.44, p&#x2009;=&#x2009;0.09) was observed in APS/SLE with PAMM vs. those without this complication. We identified that ophthalmologic retinal abnormalities occurred in more than 1/4 of asymptomatic APS/SLE and SLE. DLDs are the most frequent with similar frequencies in both conditions whereas PAMM occurred exclusively in APS/SLE patients. The possible association of the latter condition with aPL triple positivity and high aGAPSS suggests these two conditions may underlie the retinal maculopathy. Our findings in asymptomatic patients reinforce the need for early surveillance in these patients. Key Points &#x2022; Retinal abnormalities occur in more than 1/4 of asymptomatic APS/SLE and SLE patients. &#x2022; The occurrence of PAMM is possibly associated with APS and DLDs with SLE. &#x2022; Presence of aPL triple positivity and high aGAPSS seem to be risk factors for PAMM.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Neto</LastName><ForeName>Epit&#xe1;cio D S</ForeName><Initials>EDS</Initials><Identifier Source="ORCID">0000-0002-9407-1576</Identifier><AffiliationInfo><Affiliation>Division of Ophthalmology, Faculty of Medicine, Sao Paulo University, Av. Dr. Arnaldo, 455, Cerqueira C&#xe9;sar, S&#xe3;o Paulo, SP, 01246-903, Brazil. epitacio.dsneto@hc.fm.usp.br.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neto</LastName><ForeName>Taurino S R</ForeName><Initials>TSR</Initials><AffiliationInfo><Affiliation>Division of Ophthalmology, Faculty of Medicine, Sao Paulo University, Av. Dr. Arnaldo, 455, Cerqueira C&#xe9;sar, S&#xe3;o Paulo, SP, 01246-903, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Signorelli</LastName><ForeName>Fl&#xe1;vio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Faculty of Medicine, Sao Paulo University, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Balbi</LastName><ForeName>Gustavo G M</ForeName><Initials>GGM</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Faculty of Medicine, Sao Paulo University, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Higashi</LastName><ForeName>Alex H</ForeName><Initials>AH</Initials><AffiliationInfo><Affiliation>Division of Ophthalmology, Faculty of Medicine, Sao Paulo University, Av. Dr. Arnaldo, 455, Cerqueira C&#xe9;sar, S&#xe3;o Paulo, SP, 01246-903, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Monteiro</LastName><ForeName>M&#xe1;rio Luiz R</ForeName><Initials>MLR</Initials><AffiliationInfo><Affiliation>Division of Ophthalmology, Faculty of Medicine, Sao Paulo University, Av. Dr. Arnaldo, 455, Cerqueira C&#xe9;sar, S&#xe3;o Paulo, SP, 01246-903, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonf&#xe1;</LastName><ForeName>Eloisa</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Faculty of Medicine, Sao Paulo University, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Andrade</LastName><ForeName>Danieli C O</ForeName><Initials>DCO</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Faculty of Medicine, Sao Paulo University, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Zacharias</LastName><ForeName>Leandro C</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>Division of Ophthalmology, Faculty of Medicine, Sao Paulo University, Av. Dr. Arnaldo, 455, Cerqueira C&#xe9;sar, S&#xe3;o Paulo, SP, 01246-903, Brazil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Clin Rheumatol</MedlineTA><NlmUniqueID>8211469</NlmUniqueID><ISSNLinking>0770-3198</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017152">Antibodies, Antiphospholipid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016736" MajorTopicYN="Y">Antiphospholipid Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017152" MajorTopicYN="N">Antibodies, Antiphospholipid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012164" MajorTopicYN="Y">Retinal Diseases</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008268" MajorTopicYN="Y">Macular Degeneration</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antiphospholipid syndrome</Keyword><Keyword MajorTopicYN="N">Drusen-like deposits</Keyword><Keyword MajorTopicYN="N">Eye</Keyword><Keyword MajorTopicYN="N">PAMM</Keyword><Keyword MajorTopicYN="N">Retina</Keyword><Keyword MajorTopicYN="N">Systemic lupus erythematosus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>7</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>4</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>1</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>1</Day><Hour>11</Hour><Minute>6</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37126136</ArticleId><ArticleId IdType="doi">10.1007/s10067-023-06613-9</ArticleId><ArticleId IdType="pii">10.1007/s10067-023-06613-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Miyakis S, Lockshin MD, Atsumi T et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4:295&#x2013;306. https://doi.org/10.1111/j.1538-7836.2006.01753.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1538-7836.2006.01753.x</ArticleId><ArticleId IdType="pubmed">16420554</ArticleId></ArticleIdList></Reference><Reference><Citation>Vianna JL, Khamashta MA, Ordi-Ros J et al (1994) Comparison of the primary and secondary antiphospholipid syndrome: a European Multicenter Study of 114 patients. Am J Med 96:3&#x2013;9. https://doi.org/10.1016/0002-9343(94)90108-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0002-9343(94)90108-2</ArticleId><ArticleId IdType="pubmed">8304360</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine JS, Branch DW, Rauch J (2002) The antiphospholipid syndrome. N Engl J Med 346:752&#x2013;763. https://doi.org/10.1056/NEJMra002974</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra002974</ArticleId><ArticleId IdType="pubmed">11882732</ArticleId></ArticleIdList></Reference><Reference><Citation>Belizna C, Stojanovich L, Cohen-Tervaert JW, Fassot C, Henrion D, Loufrani L et al (2018) Primary antiphospholipid syndrome and antiphospholipid syndrome associated to systemic lupus: are they different entities? Autoimmun Rev 17(8):739&#x2013;745. https://doi.org/10.1016/j.autrev.2018.01.027</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2018.01.027</ArticleId><ArticleId IdType="pubmed">29885541</ArticleId></ArticleIdList></Reference><Reference><Citation>de Franco AM, Medina FMC, Balbi GGM, Levy RA, Signorelli F (2020) Ophthalmologic manifestations in primary antiphospholipid syndrome patients: a cross-sectional analysis of a primary antiphospholipid syndrome cohort (APS-Rio) and systematic review of the literature. Lupus 29(12):1528&#x2013;1543. https://doi.org/10.1177/0961203320949667</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203320949667</ArticleId><ArticleId IdType="pubmed">32814509</ArticleId></ArticleIdList></Reference><Reference><Citation>Cobo-Soriano R, S&#xe1;nchez-Ram&#xf3;n S, Aparicio MJ, Teijeiro MA, Vidal P, Su&#xe1;rez-Leoz M et al (1999) Antiphospholipid antibodies and retinal thrombosis in patients without risk factors: a prospective case-control study. Am J Ophthalmol 128(6):725&#x2013;732. https://doi.org/10.1016/s0002-9394(99)00311-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0002-9394(99)00311-6</ArticleId><ArticleId IdType="pubmed">10612509</ArticleId></ArticleIdList></Reference><Reference><Citation>Trese MGJ, Thanos A, Yonekawa Y, Randhawa S (2017) Optical coherence tomography angiography of paracentral acute middle maculopathy associated with primary antiphospholipid syndrome. Ophthalmic Surg Lasers Imaging Retina 48(2):175&#x2013;178. https://doi.org/10.3928/23258160-20170130-13</Citation><ArticleIdList><ArticleId IdType="doi">10.3928/23258160-20170130-13</ArticleId><ArticleId IdType="pubmed">28195622</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarraf D, Rahimy E, Fawzi AA et al (2013) Paracentral acute middle maculopathy: a new variant of acute macular neuroretinopathy associated with retinal capillary ischemia. JAMA Ophthalmol 131(10):1275&#x2013;1287. https://doi.org/10.1001/jamaophthalmol.2013.4056</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaophthalmol.2013.4056</ArticleId><ArticleId IdType="pubmed">23929382</ArticleId></ArticleIdList></Reference><Reference><Citation>Silpa-archa S, Lee JJ, Foster CS (2016) Ocular manifestations in systemic lupus erythematosus. Br J Ophthalmol 100:135&#x2013;141. https://doi.org/10.1136/bjophthalmol-2015-306629</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bjophthalmol-2015-306629</ArticleId><ArticleId IdType="pubmed">25904124</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoughy SS, Tabbara KF (2016) Ocular findings in systemic lupus erythematosus. Saudi J Ophthalmol 30(2):117&#x2013;121. https://doi.org/10.1016/j.sjopt.2016.02.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sjopt.2016.02.001</ArticleId><ArticleId IdType="pubmed">27330388</ArticleId><ArticleId IdType="pmc">4908056</ArticleId></ArticleIdList></Reference><Reference><Citation>- Pelegr&#xed;n L, Morat&#xf3; M, Ara&#xfa;jo O, Figueras-Roca M, Zarranz-Ventura J, Ad&#xe1;n A et al (2022) Preclinical ocular changes in systemic lupus erythematosus patients by optical coherence tomography. Rheumatology keac626. https://doi.org/10.1093/rheumatology/keac626</Citation></Reference><Reference><Citation>Arfeen SA, Bahgat N, Adel N, Eissa M, Khafagy MM (2020) Assessment of superficial and deep retinal vessel density in systemic lupus erythematosus patients using optical coherence tomography angiography. Graefe&#x2019;s Arch Clin Exp Ophthalmol 258:1261&#x2013;1268. https://doi.org/10.1007/s00417-020-04626-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00417-020-04626-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40(9):1725. https://doi.org/10.1002/art.1780400928</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780400928</ArticleId><ArticleId IdType="pubmed">9324032</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladman DD, Iba&#xf1;ez D, Urowitz MB (2002) Systemic lupus erythematosus disease activity index 2000. J Rheumatol 29(2):288</Citation><ArticleIdList><ArticleId IdType="pubmed">11838846</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladman D, Ginzler E, Goldsmith C et al (1996) The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 39:363&#x2013;369. https://doi.org/10.1002/art.1780390303</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780390303</ArticleId><ArticleId IdType="pubmed">8607884</ArticleId></ArticleIdList></Reference><Reference><Citation>Amigo M-C, Goycochea-Robles MV, Espinosa-Cuervo G, Medina G, Barrag&#xe1;n-Garfias JA, Vargas A et al (2015) Development and initial validation of a damage index (DIAPS) in patients with thrombotic antiphospholipid syndrome (APS). Lupus 24(9):927&#x2013;934. https://doi.org/10.1177/09612033155768</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/09612033155768</ArticleId><ArticleId IdType="pubmed">25767071</ArticleId></ArticleIdList></Reference><Reference><Citation>Chylack LT, Wolfe JK, Singer DM et al (1993) The lens opacities classification system III. Arch Ophthalmol 111(6):831&#x2013;836. https://doi.org/10.1001/archopht.1993.01090060119035</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archopht.1993.01090060119035</ArticleId><ArticleId IdType="pubmed">8512486</ArticleId></ArticleIdList></Reference><Reference><Citation>Voleti VB, Hubschman J-P (2013) Age-related eye disease. Maturitas 75(1):29&#x2013;33. https://doi.org/10.1016/j.maturitas.2013.01.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.maturitas.2013.01.018</ArticleId><ArticleId IdType="pubmed">23474322</ArticleId></ArticleIdList></Reference><Reference><Citation>Klinkhoff AV, Beattie CW, Chalmers A (1986) Retinopathy in systemic lupus erythematosus: relationship to disease activity. Arthritis Rheum 29(9):1152&#x2013;1156. https://doi.org/10.1002/art.1780290914</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780290914</ArticleId><ArticleId IdType="pubmed">3753541</ArticleId></ArticleIdList></Reference><Reference><Citation>Marmor MF, Kellner U, Lai TYY, Melles RB, Mieler WF (2016) Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 Revision). Ophthalmol 123(6):1386&#x2013;1394. https://doi.org/10.1016/j.ophtha.2016.01.058</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2016.01.058</ArticleId></ArticleIdList></Reference><Reference><Citation>Spaide RF, Fujimoto JG, Waheed NK, Sadda SR, Staurenghi G (2018) Optical coherence tomography angiography. Prog Retin Eye Res 64:1&#x2013;55. https://doi.org/10.1016/j.preteyeres.2017.11.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.preteyeres.2017.11.003</ArticleId><ArticleId IdType="pubmed">29229445</ArticleId></ArticleIdList></Reference><Reference><Citation>Read RW (2004) Clinical mini-review: systemic lupus erythematosus and the eye. Ocul Immunol Inflamm 12:87&#x2013;99. https://doi.org/10.1080/09273940490895308</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/09273940490895308</ArticleId><ArticleId IdType="pubmed">15512979</ArticleId></ArticleIdList></Reference><Reference><Citation>Alderaan K, Sekicki V, Magder LS, Petri M (2015) Risk factors for cataracts in systemic lupus erythematosus (SLE). Rheumatol Int 35(4):701&#x2013;708. https://doi.org/10.1007/s00296-014-3129-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-014-3129-5</ArticleId><ArticleId IdType="pubmed">25257763</ArticleId></ArticleIdList></Reference><Reference><Citation>Dias-Santos A, Proenca RP, Tavares Ferreira J et al (2018) The role of ophthalmic imaging in central nervous system degeneration in systemic lupus erythematosus. Autoimmun Rev 17:617&#x2013;624. https://doi.org/10.1016/j.autrev.2018.01.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2018.01.011</ArticleId><ArticleId IdType="pubmed">29635076</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold D, Morris D, Henkind P (1972) Ocular findings in systemic lupus erythematosus. Br J Ophthalmol 56(11):800. https://doi.org/10.1136/bjo.56.11.800</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bjo.56.11.800</ArticleId><ArticleId IdType="pubmed">4647128</ArticleId><ArticleId IdType="pmc">1214747</ArticleId></ArticleIdList></Reference><Reference><Citation>Utz VM, Tang J (2011) Ocular manifestations of the antiphospholipid syndrome. Br J Ophthalmol 95:454&#x2013;459. https://doi.org/10.1136/bjo.2010.182857</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bjo.2010.182857</ArticleId><ArticleId IdType="pubmed">20693557</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu W, Wu Y, Xu M et al (2016) Correction: antiphospholipid antibody and risk of retinal vein occlusion: a systematic review and meta-analysis. PLoS One 11:0157536. https://doi.org/10.1371/journal.pone.0157536</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0157536</ArticleId></ArticleIdList></Reference><Reference><Citation>Lally DR, Baumal C (2014) Subretinal drusenoid deposits associated with complement- mediated IgA nephropathy. JAMA Ophthalmol 132(6):775&#x2013;777. https://doi.org/10.1001/jamaophthalmol.2014.387</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaophthalmol.2014.387</ArticleId><ArticleId IdType="pubmed">24921170</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;souza Y, Short CD, McLeod D, Bonshek RE (2008) Long-term follow-up of drusen-like lesions in patients with type II mesangiocapillary glomerulonephritis. Br J Ophthalmol 92(7):950&#x2013;953. https://doi.org/10.1136/bjo.2007.130138</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bjo.2007.130138</ArticleId><ArticleId IdType="pubmed">18577648</ArticleId></ArticleIdList></Reference><Reference><Citation>Invernizzi A, dell&#x2019;Arti L, Leone G, Galimberti D, Garoli E, Moroni G, Santaniello A, Agarwal A, Viola F (2017) Drusen-like deposits in young adults diagnosed with systemic lupus erythematosus. Am J Ophthalmol 175:68&#x2013;76. https://doi.org/10.1016/j.ajo.2016.11.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajo.2016.11.014</ArticleId><ArticleId IdType="pubmed">27939560</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullins RF, Aptsiauri N, Hageman GS (2001) Structure and composition of drusen associated with glomerulonephritis: implications for the role of complement activation in drusen biogenesis. Eye 15:390&#x2013;395. https://doi.org/10.1038/eye.2001.142</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/eye.2001.142</ArticleId><ArticleId IdType="pubmed">11450763</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalvin LA, Fervenza FC, Sethi S, Pulido JS (2016) Shedding light on fundus drusen associated with membranoproliferative glomerulonephritis: breaking stereotypes of types I, II, and III. Retin Cases Brief Rep 10(1):72&#x2013;78. https://doi.org/10.1097/ICB.0000000000000164</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ICB.0000000000000164</ArticleId><ArticleId IdType="pubmed">26110522</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung CMG, Lee WK, Koizumi H, Dansingani K, Lai TYY, Freund KB (2019) Pachychoroid Disease Eye 33(1):14&#x2013;33. https://doi.org/10.1038/s41433-018-0158-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41433-018-0158-4</ArticleId><ArticleId IdType="pubmed">29995841</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodwin D (2014) Homonymous hemianopia: challenges and solutions. Clin Ophthalmol 8:1919&#x2013;1927. https://doi.org/10.2147/OPTH.S59452</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/OPTH.S59452</ArticleId><ArticleId IdType="pubmed">25284978</ArticleId><ArticleId IdType="pmc">4181645</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang HK, Moon KW, Ji MJ, Han SB, Hwang JM (2018) Primary antiphospholipid syndrome presenting with homonymous quadrantanopsia. Am J Ophthalmol Case Reports 10:208&#x2013;210. https://doi.org/10.1016/j.ajoc.2018.03.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajoc.2018.03.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Scharf J, Freund KB, Sadda S, Sarraf D (2021) Paracentral acute middle maculopathy and the organization of the retinal capillary plexuses. Prog Retin Eye Res 81:100884. https://doi.org/10.1016/j.preteyeres.2020.100884</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.preteyeres.2020.100884</ArticleId><ArticleId IdType="pubmed">32783959</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura M, Katagiri S, Hayashi T et al (2019) Longitudinal follow-up of two patients with isolated paracentral acute middle maculopathy. Int Med Case Rep J 12:143&#x2013;149. https://doi.org/10.2147/IMCRJ.S196047</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IMCRJ.S196047</ArticleId><ArticleId IdType="pubmed">31191041</ArticleId><ArticleId IdType="pmc">6511651</ArticleId></ArticleIdList></Reference><Reference><Citation>Moura-Coelho N, Gaspar T, Ferreira JT, Dutra-Medeiros M, Cunha JP (2020) Paracentral acute middle maculopathy-review of the literature. Graefes Arch Clin Exp Ophthalmol 258(12):2583&#x2013;2596. https://doi.org/10.1007/s00417-020-04826-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00417-020-04826-1</ArticleId><ArticleId IdType="pubmed">32661700</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarinci F, Varano M, Parravano M (2019) Retinal sensitivity loss correlates with deep capillary plexus impairment in diabetic macular ischemia. J Ophthalmol 2019:7589841. https://doi.org/10.1155/2019/7589841</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2019/7589841</ArticleId><ArticleId IdType="pubmed">31737359</ArticleId><ArticleId IdType="pmc">6815547</ArticleId></ArticleIdList></Reference><Reference><Citation>Neto TS, Neto ED, Balbi GG, Signorelli F, Higashi AH, Monteiro MLR et al (2022) Ocular findings in asymptomatic patients with primary antiphospholipid syndrome. Lupus 31(14):1800&#x2013;1807. https://doi.org/10.1177/09612033221133687</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/09612033221133687</ArticleId><ArticleId IdType="pubmed">36239237</ArticleId></ArticleIdList></Reference><Reference><Citation>Chin D, Gan NY, Holder GE, Tien M, Agrawal R, Manghani M (2021) Severe retinal vasculitis in systemic lupus erythematosus leading to vision threatening paracentral acute middle maculopathy. Mod Rheumatol Case Rep 5(2):265&#x2013;271. https://doi.org/10.1080/24725625.2021.1893961</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/24725625.2021.1893961</ArticleId><ArticleId IdType="pubmed">33627049</ArticleId></ArticleIdList></Reference><Reference><Citation>Jammal AA, Ogata NG, Daga FB, Abe RY, Costa VP, Medeiros FA (2019) What is the amount of visual field loss associated with disability in glaucoma? Am J Ophthalmol 197:45&#x2013;52. https://doi.org/10.1016/j.ajo.2018.09.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajo.2018.09.002</ArticleId><ArticleId IdType="pubmed">30236774</ArticleId></ArticleIdList></Reference><Reference><Citation>Pengo V, Ruffatti A, Legnani C, Gresele P, Barcellona D, Erba N et al (2010) Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost 8(2):237&#x2013;242. https://doi.org/10.1111/j.1538-7836.2009.03674.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1538-7836.2009.03674.x</ArticleId><ArticleId IdType="pubmed">19874470</ArticleId></ArticleIdList></Reference><Reference><Citation>Pengo V, Ruffatti A, Legnani C, Testa S, Fierro T, Marongiu F et al (2011) Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood 118(17):4714&#x2013;4718. https://doi.org/10.1182/blood-2011-03-340232</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2011-03-340232</ArticleId><ArticleId IdType="pubmed">21765019</ArticleId></ArticleIdList></Reference><Reference><Citation>Radin M, Sciascia S, Erkan D, Pengo V, Tektonidou MG, Ugarte A et al (2019) The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: results from the APS ACTION cohort. Semin Arthritis Rheum 49(3):464&#x2013;468. https://doi.org/10.1016/j.semarthrit.2019.04.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2019.04.009</ArticleId><ArticleId IdType="pubmed">31153708</ArticleId><ArticleId IdType="pmc">7402528</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>